How much revenue did Eurobio Scientific generate this year?
Eurobio Scientific has achieved a revenue of 142.14 M EUR this year.
Eurobio Scientific Revenue 2024
Eurobio Scientific Revenue
142.14 M EUR
Ticker
ALERS.PA
ISIN
FR0013240934
WKN
A2DVTN
In 2024, Eurobio Scientific's sales reached 142.14 M EUR, a 9.34% difference from the 130 M EUR sales recorded in the previous year.
The Eurobio Scientific Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 160.89 | 38,07 |
| 2025e | 152.54 | 40,15 |
| 2024e | 142.14 | 43,09 |
| 2023 | 130 | 47,11 |
| 2022 | 152.61 | 46,49 |
| 2021 | 184.71 | 55,35 |
| 2020 | 188.86 | 58,46 |
| 2019 | 59.07 | 33,14 |
| 2018 | 50.54 | 36,56 |
| 2017 | 42.67 | 35,05 |
| 2016 | 27.72 | 28,38 |
| 2015 | 29.46 | 28,30 |
| 2014 | 30.62 | 43,10 |
| 2013 | 30.5 | 46,82 |
| 2012 | 5.39 | 91,65 |
| 2011 | 4.99 | 1227,31 |
| 2010 | 8.42 | 727,35 |
| 2009 | 4.89 | 1252,41 |
| 2008 | 4.22 | 1451,26 |
| 2007 | 5.39 | 1136,23 |
| 2006 | 5.64 | 1085,87 |
| 2005 | 4.55 | 1346,00 |
| 2004 | 4.23 | 1447,83 |
Eurobio Scientific Revenue, EBIT, Net Income FR0013240934 · A2DVTN
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Eurobio Scientific, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eurobio Scientific from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eurobio Scientific’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Eurobio Scientific. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Eurobio Scientific’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Eurobio Scientific’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eurobio Scientific’s growth potential.
Eurobio Scientific Revenue, EBIT and net profit per share
| Date | Eurobio Scientific Revenue | Eurobio Scientific EBIT | Eurobio Scientific Net Income |
|---|---|---|---|
| 2026e | 160.89 M EUR | 32.14 M EUR | 14.99 M EUR |
| 2025e | 152.54 M EUR | 27.81 M EUR | 11.72 M EUR |
| 2024e | 142.14 M EUR | 24 M EUR | 9.29 M EUR |
| 2023 | 130 M EUR | 14.54 M EUR | 4.84 M EUR |
| 2022 | 152.61 M EUR | 30.87 M EUR | 24.94 M EUR |
| 2021 | 184.71 M EUR | 70.12 M EUR | 60.54 M EUR |
| 2020 | 188.86 M EUR | 81.21 M EUR | 73.48 M EUR |
| 2019 | 59.07 M EUR | 569,000 EUR | 3.15 M EUR |
| 2018 | 50.54 M EUR | -1.16 M EUR | -2.77 M EUR |
| 2017 | 42.67 M EUR | -5.79 M EUR | -9.97 M EUR |
| 2016 | 27.72 M EUR | -7.39 M EUR | -7.73 M EUR |
| 2015 | 29.46 M EUR | -8.34 M EUR | -5.88 M EUR |
| 2014 | 30.62 M EUR | -5.69 M EUR | -5.49 M EUR |
| 2013 | 30.5 M EUR | -7.03 M EUR | -5.99 M EUR |
| 2012 | 5.39 M EUR | -6.55 M EUR | -5.77 M EUR |
| 2011 | 4.99 M EUR | -8.1 M EUR | -7.1 M EUR |
| 2010 | 8.42 M EUR | -6.97 M EUR | -7.75 M EUR |
| 2009 | 4.89 M EUR | -9.66 M EUR | -7.7 M EUR |
| 2008 | 4.22 M EUR | -11.39 M EUR | -8.93 M EUR |
| 2007 | 5.39 M EUR | -7.79 M EUR | -7.34 M EUR |
| 2006 | 5.64 M EUR | -4.98 M EUR | -4.53 M EUR |
| 2005 | 4.55 M EUR | -4.84 M EUR | -4.24 M EUR |
| 2004 | 4.23 M EUR | -10.15 M EUR | -11.47 M EUR |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 4.23 M EUR | -10.15 M EUR | -11.47 M EUR |
| 2005 | 4.55 M EUR | -4.84 M EUR | -4.24 M EUR |
| 2006 | 5.64 M EUR | -4.98 M EUR | -4.53 M EUR |
| 2007 | 5.39 M EUR | -7.79 M EUR | -7.34 M EUR |
| 2008 | 4.22 M EUR | -11.39 M EUR | -8.93 M EUR |
| 2009 | 4.89 M EUR | -9.66 M EUR | -7.7 M EUR |
| 2010 | 8.42 M EUR | -6.97 M EUR | -7.75 M EUR |
| 2011 | 4.99 M EUR | -8.1 M EUR | -7.1 M EUR |
| 2012 | 5.39 M EUR | -6.55 M EUR | -5.77 M EUR |
| 2013 | 30.5 M EUR | -7.03 M EUR | -5.99 M EUR |
| 2014 | 30.62 M EUR | -5.69 M EUR | -5.49 M EUR |
| 2015 | 29.46 M EUR | -8.34 M EUR | -5.88 M EUR |
| 2016 | 27.72 M EUR | -7.39 M EUR | -7.73 M EUR |
| 2017 | 42.67 M EUR | -5.79 M EUR | -9.97 M EUR |
| 2018 | 50.54 M EUR | -1.16 M EUR | -2.77 M EUR |
| 2019 | 59.07 M EUR | 569,000 EUR | 3.15 M EUR |
| 2020 | 188.86 M EUR | 81.21 M EUR | 73.48 M EUR |
| 2021 | 184.71 M EUR | 70.12 M EUR | 60.54 M EUR |
| 2022 | 152.61 M EUR | 30.87 M EUR | 24.94 M EUR |
| 2023 | 130 M EUR | 14.54 M EUR | 4.84 M EUR |
| 2024e | 142.14 M EUR | 24 M EUR | 9.29 M EUR |
| 2025e | 152.54 M EUR | 27.81 M EUR | 11.72 M EUR |
| 2026e | 160.89 M EUR | 32.14 M EUR | 14.99 M EUR |
Eurobio Scientific stock margins FR0013240934 · A2DVTN
The Eurobio Scientific margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eurobio Scientific. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eurobio Scientific.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Eurobio Scientific's sales revenue. A higher gross margin percentage indicates that the Eurobio Scientific retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Eurobio Scientific's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Eurobio Scientific's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eurobio Scientific's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eurobio Scientific. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eurobio Scientific's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Eurobio Scientific Margin History
| Eurobio Scientific Gross margin | Eurobio Scientific Profit margin | Eurobio Scientific EBIT margin | Eurobio Scientific Profit margin |
|---|---|---|---|
| 2026e | 47.11 % | 19.97 % | 9.32 % |
| 2025e | 47.11 % | 18.23 % | 7.68 % |
| 2024e | 47.11 % | 16.88 % | 6.54 % |
| 2023 | 47.11 % | 11.18 % | 3.72 % |
| 2022 | 46.49 % | 20.23 % | 16.34 % |
| 2021 | 55.35 % | 37.96 % | 32.78 % |
| 2020 | 58.46 % | 43 % | 38.91 % |
| 2019 | 33.14 % | 0.96 % | 5.34 % |
| 2018 | 36.56 % | -2.29 % | -5.48 % |
| 2017 | 35.05 % | -13.56 % | -23.36 % |
| 2016 | 28.38 % | -26.66 % | -27.9 % |
| 2015 | 28.3 % | -28.31 % | -19.95 % |
| 2014 | 43.1 % | -18.58 % | -17.92 % |
| 2013 | 46.82 % | -23.05 % | -19.64 % |
| 2012 | 91.65 % | -121.52 % | -107.05 % |
| 2011 | 47.11 % | -162.32 % | -142.28 % |
| 2010 | 47.11 % | -82.78 % | -92.04 % |
| 2009 | 47.11 % | -197.55 % | -157.46 % |
| 2008 | 47.11 % | -269.91 % | -211.61 % |
| 2007 | 47.11 % | -144.53 % | -136.18 % |
| 2006 | 47.11 % | -88.3 % | -80.32 % |
| 2005 | 47.11 % | -106.37 % | -93.19 % |
| 2004 | 47.11 % | -239.95 % | -271.16 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 47.11 % | -239.95 % | -271.16 % |
| 2005 | 47.11 % | -106.37 % | -93.19 % |
| 2006 | 47.11 % | -88.3 % | -80.32 % |
| 2007 | 47.11 % | -144.53 % | -136.18 % |
| 2008 | 47.11 % | -269.91 % | -211.61 % |
| 2009 | 47.11 % | -197.55 % | -157.46 % |
| 2010 | 47.11 % | -82.78 % | -92.04 % |
| 2011 | 47.11 % | -162.32 % | -142.28 % |
| 2012 | 91.65 % | -121.52 % | -107.05 % |
| 2013 | 46.82 % | -23.05 % | -19.64 % |
| 2014 | 43.1 % | -18.58 % | -17.92 % |
| 2015 | 28.3 % | -28.31 % | -19.95 % |
| 2016 | 28.38 % | -26.66 % | -27.9 % |
| 2017 | 35.05 % | -13.56 % | -23.36 % |
| 2018 | 36.56 % | -2.29 % | -5.48 % |
| 2019 | 33.14 % | 0.96 % | 5.34 % |
| 2020 | 58.46 % | 43 % | 38.91 % |
| 2021 | 55.35 % | 37.96 % | 32.78 % |
| 2022 | 46.49 % | 20.23 % | 16.34 % |
| 2023 | 47.11 % | 11.18 % | 3.72 % |
| 2024e | 47.11 % | 16.88 % | 6.54 % |
| 2025e | 47.11 % | 18.23 % | 7.68 % |
| 2026e | 47.11 % | 19.97 % | 9.32 % |
Eurobio Scientific Aktienanalyse
What does Eurobio Scientific do?
Eurobio Scientific SA is a French company specializing in the development and marketing of diagnostic and research products in the field of biology. It was founded in 2007 as a spin-off from the Pierre and Marie Curie University and is headquartered in Paris. Since 2017, the company has been listed on Euronext Growth in Paris. The company's business model is based on clear divisional structure with various product lines, including clinical diagnostics, research diagnostics, blood bank diagnostics, food analysis, and animal health research. Eurobio Scientific SA operates in over 60 countries and has a strong presence in Europe and Asia. Its notable products include the COVID-19 antibody test ELISA, a rapid COVID-19 test based on immuno-chromatography, and an All-In-One PCR test system for detecting COVID-19. This system allows for the rapid identification of the virus through a single reaction tube. Overall, Eurobio Scientific SA is an innovative company committed to constant product development and improvement, and its diverse product portfolio and international presence highlight its strength and position as an emerging player in the field of diagnostic and research products. Eurobio Scientific ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Eurobio Scientific's Sales Figures
The sales figures of Eurobio Scientific originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Eurobio Scientific’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Eurobio Scientific's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Eurobio Scientific’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Eurobio Scientific stock
How much was the turnover of the company Eurobio Scientific compared to the previous year?
The revenue of Eurobio Scientific has increased by 9.34% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Eurobio Scientific?
The revenue of Eurobio Scientific is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Eurobio Scientific measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Eurobio Scientific so important for investors?
The revenue of Eurobio Scientific is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Eurobio Scientific pay?
Over the past 12 months, Eurobio Scientific paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eurobio Scientific is expected to pay a dividend of 0 EUR.
What is the dividend yield of Eurobio Scientific?
The current dividend yield of Eurobio Scientific is .
When does Eurobio Scientific pay dividends?
Eurobio Scientific pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Eurobio Scientific?
Eurobio Scientific paid dividends every year for the past 0 years.
What is the dividend of Eurobio Scientific?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Eurobio Scientific located?
Eurobio Scientific is assigned to the 'Health' sector.
Wann musste ich die Aktien von Eurobio Scientific kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Eurobio Scientific from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Eurobio Scientific pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Eurobio Scientific in the year 2023?
In the year 2023, Eurobio Scientific distributed 0 EUR as dividends.
In which currency does Eurobio Scientific pay out the dividend?
The dividends of Eurobio Scientific are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Eurobio Scientific
Our stock analysis for Eurobio Scientific Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eurobio Scientific Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Eurobio Scientific Revenue
- Eurobio Scientific Net Income
- Eurobio Scientific P/E
- Eurobio Scientific P/S
- Eurobio Scientific EBIT
- Eurobio Scientific Dividend
- Eurobio Scientific Stocks
- Eurobio Scientific Market capitalization
- Eurobio Scientific Debt
- Eurobio Scientific Liabilities
- Eurobio Scientific Equity
- Eurobio Scientific AAQS
- Eurobio Scientific Employees
- Eurobio Scientific ROE
- Eurobio Scientific ROA
- Eurobio Scientific ROCE
